(Total Views: 1052)
Posted On: 10/18/2019 6:11:12 PM
Post# of 416
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Expanding Commercialization of Wearable Pain-Management Device
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, has completed clinical trials and is currently expanding commercialization of its SofPulse® device that delivers pulsed electromagnetic frequencies for pain management. An article discussing the company reads, “In August, Endonovo announced its Q2 financial results, showing growth in both revenue and gross profits. However, since the economic potential for a safe, nonaddictive alternative to opioids is significant, the company’s continued progress as it reaches developmental and test milestones is clearly the key focus. Over the second quarter of 2019, the company expanded SofPulse® commercialization and announced the first commercial sales of the device for post-operative pain and edema. ‘The opioid epidemic is a major issue in society today, making SofPulse® a significant alternative to postoperative pain management. We believe we have laid the foundation for rapid growth and expansion,’ Endonovo CEO Alan Collier said in a company news release (http://nnw.fm/2gzUv).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, has completed clinical trials and is currently expanding commercialization of its SofPulse® device that delivers pulsed electromagnetic frequencies for pain management. An article discussing the company reads, “In August, Endonovo announced its Q2 financial results, showing growth in both revenue and gross profits. However, since the economic potential for a safe, nonaddictive alternative to opioids is significant, the company’s continued progress as it reaches developmental and test milestones is clearly the key focus. Over the second quarter of 2019, the company expanded SofPulse® commercialization and announced the first commercial sales of the device for post-operative pain and edema. ‘The opioid epidemic is a major issue in society today, making SofPulse® a significant alternative to postoperative pain management. We believe we have laid the foundation for rapid growth and expansion,’ Endonovo CEO Alan Collier said in a company news release (http://nnw.fm/2gzUv).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
